← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Abvacc, Inc.
Rockville, MD
$12,176,735
Total funding
11
Grants
Funding over time
peak $5.3M · FY2021–25$10M$7.5M$5M$2.5M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,176,735 · 11
By mechanism
R44$5,492,941 · 4
R01$4,054,200 · 4
N01$1,717,967 · 1
R43$596,627 · 1
R42$315,000 · 1
Investigators at Abvacc, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Development of Therapeutic Products for Marburg Virus$1,696,004
N01 · FY2023 · AI
Immunotherapy of MRSA Osteomyelitis$1,000,000
R44 · FY2023 · AI
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$1,000,000
R44 · FY2025 · AI
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$986,248
R44 · FY2023 · AI
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$918,483
R44 · FY2024 · AI
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control$914,818
R44 · FY2025 · AI
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$670,570
R01 · FY2023 · AI
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$663,570
R01 · FY2023 · AI
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$649,379
R01 · FY2024 · AI
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease$646,138
R01 · FY2025 · AI
A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia$638,953
R01 · FY2025 · AI
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection$619,311
R01 · FY2024 · AI
Development of a Universal Immunotherapeutic for Influenza Viruses$380,000
R44 · FY2022 · AI
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$315,000
R42 · FY2021 · AI
Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist$299,528
R43 · FY2024 · AI
Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist$297,099
R43 · FY2025 · AI
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$293,392
R44 · FY2023 · AI
Rationally Designed Pan-Ebolavirus Vaccine$166,279
R01 · FY2021 · AI
Development of Therapeutic Products for Marburg Virus$21,963
N01 · FY2025 · AI